ClinicalTrials.gg
RecruitingNCT06850766TMZ-CHRONOUpdated Jul 16, 2026

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

An interventional study of Morning administration of TMZ and Evening administration of TMZ in IDH-Wildtype Glioblastoma and Glioblastoma (GBM), sponsored by Ottawa Hospital Research Institute. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Glioblastoma with a site in Canada — 17 open to participants now, 34 under way, 5 of them phase 3. Glioblastoma · Canada.

Planned enrollment
68th of 111
50 · median 74
Started
2025
with 7 others
No phase
14 of 118
3 open now
Primary completion
2027-05
later than 17 of 33 live
Registered
115th of 118
by date

Among the 118 studies in Glioblastoma with a site in Canada, this one is the 68th largest by planned enrollment of the 111 interventional ones that give a count, is one of 8 that started in 2025, is one of 14 with no phase, reaches primary completion later than 17 of the 33 other live ones, and was the 115th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

17 of the 118 studies in Glioblastoma with a site in Canada are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Glioblastoma with a site in Canada, or all of them as a file.
02

Study summary

The body's biological functions follow a circadian rhythm, meaning that individual biological functions in the body change over a 24-hour cycle. There is evidence suggesting that the body and cancer cells may react differently to anti-cancer treatment based on the time of day they are exposed. In fact, researchers have already found that giving anti-cancer treatments at a particular time of the day works better in rectal and ovarian cancer. Temozolomide (TMZ) is a chemotherapy pill/capsule commonly given to patients with newly diagnosed glioblastoma after brain surgery and radiation treatment. However, there is no current standard for what time of day TMZ should be taken for the treatment of glioblastoma.

In the current study, participants are randomly placed in one of two groups: a morning group and an evening group. Based on this group placement, participants are instructed to either take their TMZ in the morning or in the evening and record the date and time they take their TMZ in a pill diary. Participants will wear a wrist actigraphy device for the first cycle of TMZ. The primary goal of the study is to understand if taking TMZ at a prescribed time of day (morning/evening) is feasible in adults with glioblastoma. This is a pilot trial, and the investigators hypothesize that it will be feasible for glioblastoma patients to take TMZ at the prescribed time of day. The secondary goals of this study are to evaluate participant recruitment, safety, health-related quality of life, biological timing of TMZ delivery, and changes in condition over time. This pilot study will help investigators plan for a larger, pragmatic randomized clinical trial in the future.

Read the detailed description

TMZ-CHRONO is a randomized, multi-centre pilot trial evaluating the feasibility of chronotherapy (dose-timing) for temozolomide (TMZ) in IDH-wildtype glioblastoma (GBM).

The body's biological functions follow a circadian rhythm. Chronotherapy is the deliberate timing of medications to enhance therapeutic benefit and/or minimize toxicity, and can be achieved by dose-timing treatments. There is evidence suggesting that cancer cells may react differently to chemotherapy based on the time of day they are exposed. In fact, researchers have already found that giving anti-cancer treatments at a particular time of the day works better in rectal and ovarian cancer. TMZ is a standard of care treatment for GBM, however there is currently no consensus or guideline with respect to the optimal timing of adjuvant TMZ administration. The study team recently conducted systematic review on TMZ chronotherapy in the treatment of glioma. With emerging evidence that TMZ timing may be important, it is paramount to conduct a large pragmatic randomized study to assess this claim in GBM. The current study is a minimal risk pilot trial to inform the development of a larger, pragmatic randomized clinical trial in the future.

Prospective participants will be approached by their physician (or a member within the circle of care) during their routine clinic visit to begin the integrated verbal consent model process. The physician will explain that the patient is receiving standard of care treatment, with the only change being the timing of adjuvant TMZ (morning vs evening). The physician will then ask the patient for verbal consent to participate in this research study and document this consent in the patient's electronic medical record. Eligible and consenting patients will be randomized to one of two study arms (morning administration of TMZ, and evening administration of TMZ) in a 1:1 fashion using a permuted block design through the Ottawa Methods Centre. Randomization will be stratified by cancer centre [The Ottawa Hospital Cancer Centre (TOHCC) and the London Health Sciences Centre (LHSC); Canada]. The participants and investigators will not be blinded to treatment arm allocations. The participants will wear a wrist actigraphy device during the first cycle of TMZ.

The primary aim of the study is to understand if taking TMZ at a prescribed time of day (morning/evening) is feasible in adults with GBM. The secondary aims of the study are to evaluate participant recruitment, safety, health-related quality of life, biological timing of TMZ deliver, and changes in condition over time. Data is collected throughout the study at baseline, randomization, pre/post-TMZ cycles, and at 4-, 8-, 12-, 24-, and 48-weeks after baseline. The study team will continue to follow the participant conditions after TMZ completion for up to 5 years.

This pilot trial is the first and necessary step to assess the feasibility of randomized treatment allocation, rate of pill diary completion, and metrics surrounding participant accrual. This will help determine the number of recruitment sites and expected duration of accrual for a future pragmatic, randomized clinical trial on chronotherapy of TMZ in IDH-wildtype GBM.

03

Conditions studied

  • IDH-Wildtype Glioblastoma
  • Glioblastoma (GBM)

Keywords

  • temozolomide
  • chronotherapy
  • dose timing
  • cancer
  • oncology
  • glioblastoma
  • chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Newly diagnosed IDH-wildtype glioblastoma
  • Completed maximal safe brain tumor resection
  • Completed post-operative brain RT
  • Plan to proceed with up to 6 cycles of adjuvant TMZ within 8 weeks of completing post-operative RT
  • Able and willing to provide oral

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to complete study questionnaires
  • or incurable cancer other than IDH-wild type glioblastoma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Morning administration of TMZ

    Participants were instructed to take the prescribed daily dose of temozolomide (TMZ) in the morning.

    Other: Morning administration of TMZ

  • Active comparator
    Evening administration of TMZ

    Participants were instructed to take the prescribed daily dose of temozolomide (TMZ) in the evening.

    Other: Evening administration of TMZ

Interventions

  • OtherMorning administration of TMZ

    Administration of TMZ within 2 hours of waking

  • OtherEvening administration of TMZ

    Administration of TMZ within 2 hours of bedtime

06

What researchers measure

Primary outcomes

  1. Feasibility: adherence to TMZ dose timing protocol

    The primary outcome is feasibility for patients to receive temozolomide (TMZ) according to their assigned dose timing. Feasibility is measured by at least 80% adherence to the assigned TMZ dose timing. Adherence is calculated based on patient entries in a daily pill diary.

    Time frame: Patients complete daily pill diaries on days 1-5 of a 28-day cycle for up to 6 cycles. It is expected that the first cycle will begin within 8 weeks of the last fraction (dose) of radiation. Adherence is calculated at Week 48.

Secondary outcomes

  1. Participant recruitment: proportion of patients providing consent to participate

    The number of patients who provided consent for study participation over the total number of patients approached and invited to participate in the clinical study

    Time frame: The number of patients providing consent to participate will be collected during the recruitment period and the total number/proportion will be calculated upon completion of recruitment. The anticipated recruitment period length is one year.

  2. Participant recruitment: participant withdrawal rate and reasons

    Proportion of eligible patients who consented to the study, but subsequently withdrew from study prior to starting the first cycle of adjuvant temozolomide (TMZ)

    Time frame: Withdrawal rate and reasons will be collected from enrollment to start of adjuvant TMZ

  3. Participant recruitment: rate of patient enrollment

    The rate of patient enrollment is defined by the number of new study participants who were randomized per center (average number of patients per month)

    Time frame: The number of patients enrolled in the study will be collected during the recruitment period. The anticipated recruitment period is one year.

  4. Safety: rate of hospital admissions

    Rate of hospital admissions per patient defined as the number of discrete admissions to acute care facility.

    Time frame: The number of hospitalizations will be collected from the start of adjuvant TMZ until 6 weeks after the last TMZ cycle (28-day cycles for up to 6 cycles). The number of hospitalizations per participant will be calculated at Week 48.

  5. Safety: number of TMZ cycles

    The median number of cycles received per group

    Time frame: The number of TMZ cycles will be calculated at Week 48, once all questionnaires and adjuvant treatment cycles are complete.

  6. Safety: reasons for early discontinuation of adjuvant TMZ

    The reasons for early discontinuation of adjuvant TMZ, if applicable, will be collected as a safety outcome.

    Time frame: The reasons for early discontinuation of adjuvant TMZ will be collected during the treatment period: post-cycle 1, post-cycle 2, post-cycle 3, post-cycle 4, post-cycle 5. Each TMZ cycle is 28 days.

  7. Safety: rate of TMZ delay

    The rate of TMZ delay due to not meeting treatment parameters will be collected as a safety outcome.

    Time frame: TMZ delay is collected during the treatment period: post-cycle 1, post-cycle 2, post-cycle 3, post-cycle 4, post-cycle 5. Each TMZ cycle is 28 days. The rate of TMZ delay is calculated at Week 48.

  8. Health-related quality of life (HR-QoL): FACT-Br Version 4

    HR-QoL will be measured according to the Functional Assessment of Cancer Therapy -- Brain (FACT-Br) version 4. The FACT-Br includes five subscales: physical well-being (score range 0-28), social/family well-being (score range 0-28), emotional well-being (score range 0-24), functional well-being (score range 0-28), and brain cancer subscale (score range 0-92). The FACT-Br total scores range from 0 to 200. Higher scores indicate better quality of life.

    Time frame: Baseline and 4-, 8-, 12-, 24-, and 48-weeks after baseline.

  9. HR-QoL: Time to HR-QoL deterioration

    Time to health-related quality of life deterioration based on the Functional Assessment of Cancer Therapy - Brain (FACT-Br Version 4) Trial Outcome Index. The FACT-Br Trial Outcome Index includes physical well-being, functional well-being and brain subscales. The scores range from 0 to 148 and higher score indicate better quality of life.

    Time frame: FACT-Br is collected at baseline and 4-, 8-, 12-, 24-, and 48-weeks after baseline..

  10. Treatment-related side effects

    Treatment related side effects are measured with modified Functional Assessment of Cancer Therapy - Brain items: GP1 lack of energy, GP2 nausea, GP5 bother by side effects. Each of the individual items are scored from 0 to 4, where higher scores indicate worse outcome.

    Time frame: Modified FACT-Br GP1, GP2, and GP5 are collected within 1 month of each TMZ cycle (28-day cycle). Post-cycle 1, post-cycle 2, post-cycle 3, post-cycle 4, post-cycle 5, post-cycle 6.

  11. Change in Trial Outcome Index

    Functional Assessment of Cancer Therapy - Brain (FACT-Br Version 4) Trial Outcome Index includes physical well-being, functional well-being and brain subscales. The FACT-Br Trial Outcome Index scores range from 0 to 148 and higher score indicate better quality of life. This outcome measure is a change in scores.

    Time frame: Baseline to 12-weeks

  12. Change in FACT-Br scores

    Change in mean Functional Assessment of Cancer Therapy - Brain (FACT-Br Version 4) scores from baseline between treatment groups. The FACT-Br total scores range from 0 to 200 and higher scores indicate better quality of life. This outcome measure is a change in scores.

    Time frame: FACT-Br is collected at baseline and 4-, 8-, 12-, 24-, and 48-weeks after baseline.

  13. Time to first progression

    Time to first progression is defined as the time from randomization to time of investigator-assessed disease progression.

    Time frame: Disease assessment occurs prior to each TMZ cycle. Each TMZ cycle is 28 days. There is a maximum of 6 cycles.

  14. Overall survival

    Overall survival (OS) is defined as the time from randomization to time of death. Time of death is collected through chart review and physician communications. Longitudinal follow-up will continue after completion of treatment until time of death or 5 years post-randomization for collection of overall survival data.

    Time frame: Overall survival is determined at 5-years after baseline.

  15. Internal biological time of TMZ delivery

    Daily internal biological time of TMZ delivery will be calculated based on actigraphy data (wrist movements in proportional integral mode) and clock timing of TMZ administration as recorded in the pill diary and with the actigraphy event marker.

    Time frame: Post-Cycle 1. Each cycle is 28 days in length.

  16. Wall clock time of TMZ administration

    Wall clock time of TMZ administration is determined by self-reported pill diary entries and the actigraphy event marker.

    Time frame: Post-Cycle 1. Each cycle is 28 days in length.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Jia JL, Alshamsan B, Ng TL. Temozolomide Chronotherapy in Glioma: A Systematic Review. Curr Oncol. 2023 Feb 4;30(2):1893-1902. doi: 10.3390/curroncol30020147. PubMed 36826108 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 24 months is below that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 27, 2025
StartActual
May 8, 2025
Primary completionEst.
May 2027
CompletionEst.
Nov 2031
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06850766
Collaborators
The Ottawa Hospital
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
May 8, 2025
Primary completion
May 2027 (estimated)
Completion
Nov 2031 (estimated)
Last update
Jul 16, 2026

Study contacts

Lisa Vandermeer, MSc
Contact
lvandermeer@ohri.ca
613-737-7700
Danielle Allard, MSc
Contact
danallard@ohri.ca
613-737-7700
Terry Ng, MD
principal investigator · The Ottawa Hospital Cancer Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion